Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination
Global influenza circulation has been heavily suppressed by public health measures and travel restrictions since the onset of the COVID-19 pandemic.
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
These new subvariants carrying further mutations in their spike proteins raise concerns that they may further evade neutralizing antibodies.
Association of COVID-19 with New-Onset Alzheimer’s Disease
An infectious etiology of Alzheimer’s disease has been postulated for decades. It remains unknown whether SARS-CoV-2 viral infection is associated with increased risk for Alzheimer’s disease.
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years).
Scientific Papers
Article
Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study
COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection
Scientific Papers
Article
The molecular epidemiology of multiple zoonotic origins of SARS-CoV-2
Big study reveals increased heart disease and diabetes risk after COVID-19
Cardiometabolic outcomes up to 12 months after COVID-19 infection. A matched cohort study in the UK
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
The role of immune responses to previously seen endemic coronavirus epitopes in severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and disease progression has not yet been determined.
Scientific Papers
Article
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model
In this human infection challenge pilot study, adults aged 18–55 years and 60–75 years were assessed for enrolment using protocol-defined inclusion and exclusion criteria.
